|By Marketwired .||
|May 19, 2014 07:30 AM EDT||
MONTCLAIR, NJ--(Marketwired - May 19, 2014) - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that its Chairman & CEO, Thijs Spoor, will present at the 15th Annual B. Riley & Co. Investor Conference to be held at May 19
Mr. Spoor will present on Monday, May 19
About FluoroPharma Medical, Inc.
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.
FluoroPharma's initial focus is the development of breakthrough PET imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico. For more information on the company, please visit: www.fluoropharma.com
Forward Looking Statements:
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Oct. 27, 2016 02:30 PM EDT Reads: 580
Oct. 27, 2016 02:17 PM EDT Reads: 148
Oct. 27, 2016 01:48 PM EDT Reads: 213
Oct. 27, 2016 01:45 PM EDT Reads: 987
Oct. 27, 2016 01:45 PM EDT Reads: 1,138
Oct. 27, 2016 01:45 PM EDT Reads: 3,993
Oct. 27, 2016 01:45 PM EDT Reads: 1,588
Oct. 27, 2016 01:30 PM EDT Reads: 2,268
Oct. 27, 2016 01:15 PM EDT Reads: 5,079
Oct. 27, 2016 01:15 PM EDT Reads: 1,198
Oct. 27, 2016 01:15 PM EDT Reads: 830
Oct. 27, 2016 01:00 PM EDT Reads: 4,648
Oct. 27, 2016 01:00 PM EDT Reads: 355
Oct. 27, 2016 01:00 PM EDT Reads: 8,616
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
Oct. 27, 2016 12:00 PM EDT Reads: 709